HighMark Wealth Management Buys 158,855 Shares of Axogen Stock

4 weeks ago 3

John Ballard, The Motley Fool

Tue, February 24, 2026 astatine 8:19 AM CST 4 min read

In its fourth-quarter 13F filing, HighMark Wealth Management LLC disclosed a acquisition of 158,855 shares successful Axogen (NASDAQ:AXGN) . This acquisition makes the banal 1 of the firm’s largest holdings.

According to its Feb. 4, 2026, SEC filing, HighMark Wealth Management LLC accrued its presumption successful Axogen. The estimated worth of the shares acquired was astir $4 million, based connected the mean fourth-quarter trading price. This brought the worth of the Axogen holding to $11.2 cardinal arsenic of Dec. 31, 2025, an summation of $7.9 cardinal from the anterior play — reflecting banal purchases and terms movements.

HighMark Wealth Management LLC’s bargain raised its Axogen involvement to 4.6% of 13F AUM.
Top holdings aft the filing:
- NYSEMKT:IVV: $75.5 cardinal (30.8% of AUM)
- NYSEMKT:EFV: $15.9 cardinal (6.5% of AUM)
- NYSEMKT:IWM: $13.2 cardinal (5.4% of AUM)
- NYSE:AXGN: $11.2 cardinal (4.6% of AUM)
- NYSEMKT:IJR: $10.3 cardinal (4.2% of AUM)
As of Feb. 4, 2026, shares of Axogen were trading astatine $34.22, up 89.3% implicit the past twelvemonth and outperforming the S&P 500 by 75.3 percent points.
Axogen’s trailing twelve-month gross was $225 million, with a nett nonaccomplishment of $15 cardinal and a five-year gross compound yearly instrumentality of 11.9%.
The money reported 588 positions and $245 cardinal successful reportable U.S. equity assets arsenic of Dec. 31, 2025.

Metric

Value

Market Capitalization	$1.77 billion
Revenue (TTM)	$225.2 million
Net Income (TTM)	($15.7 million)
Price (as of marketplace adjacent February 4, 2026)	$34.22

Develops and markets surgical solutions for peripheral nervus repair, including Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, and Avive Soft Tissue Membrane.
Generates gross done income of proprietary nervus repair and extortion products to hospitals, country centers, and subject hospitals.
Targets integrative reconstructive, orthopedic, hand, and oral/maxillofacial surgeons successful the United States and planetary markets.

Axogen is simply a healthcare institution specializing successful innovative surgical solutions for peripheral nervus injuries, with a divers merchandise portfolio addressing nervus repair and extortion needs. The institution leverages proprietary biologic and extracellular matrix technologies to present off-the-shelf grafts and coaptation aids, supporting improved objective outcomes without the request for autograft harvesting. Axogen's strategical absorption connected expanding its addressable marketplace and serving specialized surgical disciplines underpins its competitory positioning successful the aesculapian instrumentality sector.

Read Entire Article